Research from Yonsei University Yields New Findings on Therapeutics (Anticancer drug-incorporated layered double hydroxide nanohybrids and their enhanced anticancer therapeutic efficacy in combination cancer treatment)
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Therapeutics is now available. According to news reporting out of Wonju, South Korea, by NewsRx editors, research stated, "Layered double hydroxide (LDH) nanoparticles have been studied as cellular delivery carriers for anionic anticancer agents. As MTX and 5-FU are clinically utilized anticancer drugs in combination therapy, we aimed to enhance the therapeutic performance with the help of LDH nanoparticles."
Our news journalists obtained a quote from the research from Yonsei University, "Anticancer drugs, MTX and 5-FU, and their combination, were incorporated into LDH by reconstruction method. Simply, LDHs were thermally pretreated at 400°C, and then reacted with drug solution to simultaneously form drug-incorporated LDH. Thus prepared MTX/LDH (ML), 5-FU/LDH (FL), and (MTX + 5-FU)/LDH (MFL) nanohybrids were characterized by X-ray diffractometer, scanning electron microscopy, infrared spectroscopy, thermal analysis, zeta potential measurement, dynamic light scattering, and so forth. The nanohybrids were administrated to the human cervical adenocarcinoma, HeLa cells, in concentration-dependent manner, comparing with drug itself to verify the enhanced therapeutic efficacy. All the nanohybrids successfully accommodated intended drug molecules in their house-of-card-like structures during reconstruction reaction."
According to the news editors, the research concluded: "It was found that the anticancer efficacy of MFL nanohybrid was higher than other nanohybrids, free drugs, or their mixtures, which means the multidrug-incorporated LDH nanohybrids could be potential drug delivery carriers for efficient cancer treatment via combination therapy."
For more information on this research see: Anticancer drug-incorporated layered double hydroxide nanohybrids and their enhanced anticancer therapeutic efficacy in combination cancer treatment. Biomed Research International, 2014;2014():193401 (see also Therapeutics).
Our news journalists report that additional information may be obtained by contacting T.H. Kim, Dept. of Chemistry & Medical Chemistry, College of Science & Technology, Yonsei University, Wonju, Gangwon-do 220-710, South Korea. Additional authors for this research include G.J. Lee, J.H. Kang, H.J. Kim, T.I. Kim and J.M Oh.
Keywords for this news article include: Asia, Wonju, Anions, Cancer, Alkalies, Oncology, Hydroxides, South Korea, Nanoparticle, Therapeutics, Nanotechnology, Inorganic Chemicals, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC